.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Dow
Mallinckrodt
UBS
Moodys
Covington
Johnson and Johnson
Teva
Colorcon

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,338,428

« Back to Dashboard

Which drugs does patent 8,338,428 protect, and when does it expire?


Patent 8,338,428 protects ABILIFY MAINTENA KIT and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 8,338,428

Title:Methods for administering aripiprazole
Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
Inventor(s): Brown; Josiah (Seattle, WA)
Assignee: Alkermes, Inc. (Waltham, MA)
Application Number:13/420,822
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-001Feb 28, 2013RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-001Feb 28, 2013RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-003Sep 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-003Sep 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-002Feb 28, 2013RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-002Feb 28, 2013RXYesYes► Subscribe► Subscribe► SubscribeYUSE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-004Sep 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
Otsuka Pharm Co LtdABILIFY MAINTENA KITaripiprazoleFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-004Sep 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SCHIZOPHRENIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,338,428

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,338,427Methods for administering aripiprazole► Subscribe
8,759,351Methods for administering aripiprazole► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,338,428

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1845721► Subscribe
Canada2534997► Subscribe
China102133171► Subscribe
Cyprus1111874► Subscribe
Denmark1660037► Subscribe
European Patent Office1660037► Subscribe
European Patent Office2340810► Subscribe
Spain2369893► Subscribe
Hong Kong1091725► Subscribe
CroatiaP20110646► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
Merck
Julphar
Dow
Baxter
McKesson
Fuji
Healthtrust
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot